1. SHORT-TERM COMPUTER-ASSISTED QUANTIFICATION OF PLUS DISEASE AFTER TREATMENT OF TYPE 1 RETINOPATHY OF PREMATURITY WITH INTRAVITREAL BEVACIZUMAB OR RETINAL LASER PHOTOCOAGULATION
- Author
-
Sharon F. Freedman, Thomas Chia, Kevin R. Gertsch, Leona Ding, David K. Wallace, J. Niklas Ulrich, and Michelle T. Cabrera
- Subjects
Male ,Vascular Endothelial Growth Factor A ,medicine.medical_specialty ,genetic structures ,Bevacizumab ,Angiogenesis Inhibitors ,Gestational Age ,01 natural sciences ,03 medical and health sciences ,0302 clinical medicine ,Retinal Diseases ,Ophthalmology ,medicine ,Humans ,Retinopathy of Prematurity ,Diagnosis, Computer-Assisted ,0101 mathematics ,Intravitreal bevacizumab ,Retrospective Studies ,Laser Coagulation ,business.industry ,010102 general mathematics ,Infant, Newborn ,Infant ,Retinal Vessels ,Retinopathy of prematurity ,General Medicine ,medicine.disease ,Plus disease ,Infant, Extremely Low Birth Weight ,Treatment modality ,Intravitreal Injections ,030221 ophthalmology & optometry ,Female ,sense organs ,Retinal laser photocoagulation ,business ,Infant, Premature ,After treatment ,medicine.drug - Abstract
PURPOSE To compare objectively measured changes in plus disease after bevacizumab and laser for Type 1 retinopathy of prematurity. METHODS ROPtool (a computer program) analyzed fundus images at baseline, 1 week, and subsequent examinations. RESULTS Six infants (9 eyes) were treated with bevacizumab and 7 (12 eyes) with laser. One week after treatment, bevacizumab compared with laser resulted in a greater median percent change from pretreatment in tortuosity (-53.8 vs. -0.2%, P < 0.001) and overall plus disease (-20.1 vs. -3.1%, P < 0.001). Change in dilation did not differ (-3.5 vs. -5.5%, P = 0.48). After week 1, all median ROPtool parameters continued to decrease for both groups. At last follow-up (median 3, range: 2-10 weeks), both bevacizumab and laser significantly decreased tortuosity (-54.3 and -23.8%), dilation (-8.7 and -7.5%), and overall plus disease (-27.3 and -10.3%). CONCLUSION Improvement in plus disease, in particular tortuosity, likely occurs more quickly after bevacizumab compared with laser, particularly at 1 week after treatment. These results guide clinical expectations for plus disease resolution after both treatment modalities.
- Published
- 2021
- Full Text
- View/download PDF